These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15144349)

  • 21. Tibolone: the way to beat many a postmenopausal ailments.
    Lazovic G; Radivojevic U; Marinkovic J
    Expert Opin Pharmacother; 2008 Apr; 9(6):1039-47. PubMed ID: 18377345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.
    Dimitrakakis C; Keramopoulos D; Vourli G; Gaki V; Bredakis N; Keramopoulos A
    Climacteric; 2005 Dec; 8(4):342-51. PubMed ID: 16390769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Some comments on the Million Women Study.
    Neves-E-Castro M
    Climacteric; 2003 Dec; 6(4):357. PubMed ID: 15006258
    [No Abstract]   [Full Text] [Related]  

  • 24. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
    Hammar ML; van de Weijer P; Franke HR; Pornel B; von Mauw EM; Nijland EA;
    BJOG; 2007 Dec; 114(12):1522-9. PubMed ID: 17995496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effects of tibolone on ocular functions in postmenopausal women.
    Verit FF; Oguz H; Ozkul Y; Bozkurt O
    Arch Gynecol Obstet; 2007 Apr; 275(4):255-61. PubMed ID: 17047975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tibolone revisited: still a good treatment option for healthy, early postmenopausal women.
    Kenemans P
    Gynecol Endocrinol; 2010 Apr; 26(4):237-9. PubMed ID: 20017707
    [No Abstract]   [Full Text] [Related]  

  • 27. Tibolone is not used as a first-line therapy: implications for the Million Women Study analysis.
    Seeley T
    J Br Menopause Soc; 2006 Jun; 12(2):81. PubMed ID: 16776860
    [No Abstract]   [Full Text] [Related]  

  • 28. Tibolone reduces osteoporotic fracture risk and breast cancer risk, but increases the risk of stroke.
    de Melo NR; Pompei LM
    Gynecol Endocrinol; 2010 Feb; 26(2):73-5. PubMed ID: 19995151
    [No Abstract]   [Full Text] [Related]  

  • 29. Hormone replacement therapy use and variations in the risk of breast cancer.
    Opatrny L; Dell'Aniello S; Assouline S; Suissa S
    BJOG; 2008 Jan; 115(2):169-75; discussion 175. PubMed ID: 18081598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of tibolone on blood flow resistance and intima-media thickness of the carotid arteries: effect of time since menopause.
    Somunkiran A; Yazici B; Demirci F; Erdogmus B; Ozdemir I
    Climacteric; 2006 Feb; 9(1):59-65. PubMed ID: 16428126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of different hormonal therapies on thyroid function in surgical menopause: short-term results.
    Erel CT; Gezer A; Sentürk LM; Somunkiran A; Kaleli S; Seyisoglu H
    J Reprod Med; 2007 Dec; 52(12):1079-84. PubMed ID: 18210897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tibolone (Livial) enhances warfarin-induced anticoagulation in postmenopausal women.
    Elbers J; Hageluken C; Wadham A
    Maturitas; 2007 Jan; 56(1):94-100. PubMed ID: 16887301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tibolone and Breast Tissue: a Review.
    Lello S; Capozzi A; Scambia G; Franceschini G
    Reprod Sci; 2023 Dec; 30(12):3403-3409. PubMed ID: 37450250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study.
    Bots ML; Evans GW; Riley W; McBride KH; Paskett ED; Helmond FA; Grobbee DE;
    Eur Heart J; 2006 Mar; 27(6):746-55. PubMed ID: 16415304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause.
    Perrone G; Capri O; Galoppi P; Brunelli R; Bevilacqua E; Ceci F; Ciarla MV; Strom R
    Gynecol Obstet Invest; 2009; 68(1):33-9. PubMed ID: 19349712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tibolone in the treatment of menopause: compliance, efficacy and safety in a ten year experience.
    Bianco V; Murina F; Roberti P; Valente I
    Minerva Ginecol; 2006 Aug; 58(4):335-44. PubMed ID: 16957677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
    Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
    Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of different preparations of hormone therapy on tumor necrosis factor-alpha levels in women with surgical menopause.
    Somunkiran A; Coskun A; Demirci F; Yucel O
    Gynecol Endocrinol; 2008 Feb; 24(2):79-83. PubMed ID: 18210330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of tibolone versus 17beta-estradiol on climacteric symptoms in women with surgical menopause: a randomized, cross-over study.
    Somunkiran A; Erel CT; Demirci F; Senturk ML
    Maturitas; 2007 Jan; 56(1):61-8. PubMed ID: 16831525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of hormone treatment on hemostasis variables.
    Kluft C
    Climacteric; 2007 Oct; 10 Suppl 2():32-7. PubMed ID: 17882670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.